PATIENT OR CAREGIVER
Home  |  Privacy Policy  |  Terms and Conditions  |  Contact Medical Information  |  Site Map

Exercise Data in Pulmonary Hypertension Associated with Scleroderma Spectrum of Diseases (PAH/SSD)

Significant Improvement in Exercise Capacity1

In a 12-week, prospective, open-label, randomized trial, statistically significant improvement was observed in exercise capacity, as measured by the 6-Minute Walk Test, in patients who received continuous intravenous epoprostenol plus conventional therapy for 12 weeks compared to those who received conventional therapy alone. Conventional therapy could include anticoagulants, oral vasodilators, supplemental oxygen, digoxin, and/or diuretics. Except for 5 NYHA Functional Class II patients, all patients were either Functional Class III or IV.2

Improvements were apparent in some patients at the end of the first week of therapy.

No statistical difference in survival over 12 weeks was observed in PAH/SSD patients treated with epoprostenol as compared to those receiving conventional therapy alone.

Read about hemodynamic data in PAH/SSD